Judge partially revives California pay-for-delay ban
17-02-2022
FTC insists generics ANI and Novitium divest IP before merger
11-11-2021
Teva sues two Indian generics over Huntington’s treatment
06-07-2021
Vivi-o / Shutterstock.com
The Association for Accessible Medicines (AAM), which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AAM, Generics, reverse payment, California, Pay-for-delay, Ninth Circuit, Kirkland & Elis
